Poseida Therapeutics(PSTX) - 2021 Q1 - Quarterly Report

Revenue Generation - The company has not generated any revenue from product sales and does not expect to do so until at least several years after obtaining regulatory approval for its product candidates[97][105]. - The company expects to finance its operations through equity offerings, debt financings, or other capital sources until it can generate substantial product revenue[105]. Product Development - The company is developing multiple CAR-T product candidates, including P-BCMA-101 and P-PSMA-101, with significant clinical trial progress reported, such as a >50% decline in PSA for one patient treated with P-PSMA-101[100]. - The company is working on a portfolio of allogeneic dual CAR product candidates, which are currently in preclinical studies, with plans to file an IND for at least one dual CAR program in 2022[102]. - The company has a significant focus on developing gene therapy product candidates that combine piggyBac technology with AAV to overcome limitations of traditional AAV gene therapy[103]. - The company is utilizing its proprietary gene engineering technologies, including the non-viral piggyBac DNA Delivery System and Cas-CLOVER Site-specific Gene Editing System, to develop its product candidates[98][101]. - The company plans to file an IND and initiate a Phase 1 clinical trial for P-BCMA-ALLO1 and P-MUC1C-ALLO1 by the end of 2021[105]. Financial Performance - Research and development expenses increased to $29.1 million for the three months ended March 31, 2021, up from $23.4 million in the same period of 2020, representing a 24.3% increase[121]. - General and administrative expenses rose to $8.4 million for the three months ended March 31, 2021, compared to $4.9 million in the same period of 2020, reflecting a 71.4% increase[123]. - The net loss for the three months ended March 31, 2021, was $38.3 million, compared to a net loss of $28.8 million for the same period in 2020, indicating a 33.5% increase in losses[120]. - Cash used in operating activities was $39.1 million for the three months ended March 31, 2021, compared to $22.9 million for the same period in 2020, representing an increase of 70.8%[134]. - Cash provided by investing activities was $124.5 million for the three months ended March 31, 2021, primarily from maturities of short-term investments[136]. - As of March 31, 2021, the company had an accumulated deficit of $320.2 million[126]. - The company expects to continue incurring net losses and negative cash flows from operations for at least the next several years[126]. - The company raised $224.0 million from the sale of common stock in its initial public offering in July 2020[128]. - The interest expense for the three months ended March 31, 2021, was $0.8 million, slightly down from $0.9 million in the same period of 2020[124]. - The company had cash, cash equivalents, and short-term investments of $270.0 million as of March 31, 2021, expected to fund operations for at least the next twelve months[128]. - As of March 31, 2021, the company had cash, cash equivalents, and short-term investments totaling $270.0 million[150]. - The company had $30.0 million of borrowings outstanding under the 2020 Amended Loan Agreement, with a variable interest rate of 30-day LIBOR plus 6.94%[152]. Accounting and Financial Policies - The company has not engaged in any off-balance sheet arrangements since inception[145]. - The company is classified as an emerging growth company and will remain so until it exceeds $1.07 billion in annual revenue or meets other specified criteria[146][147]. - There were no significant changes to the company's critical accounting policies and estimates during the three months ended March 31, 2021[144]. - The company has not had material foreign currency transaction gains or losses, and its expenses are generally denominated in U.S. dollars[153]. - A hypothetical 10% change in interest rates would not have had a material impact on the company's consolidated financial statements[151]. - Inflation has not had a material effect on the company's consolidated financial statements[154]. - The company has entered into several license agreements with milestone and royalty payment obligations contingent upon future events[141]. - The company has not included future payments under certain agreements in its financial statements due to the contingent nature of these obligations[141].